Kyverna Therapeutics Ownership | Who Owns Kyverna Therapeutics?
Kyverna Therapeutics Ownership Summary
Kyverna Therapeutics is owned by 26.07% institutional investors, 7.07% insiders, and 66.85% retail investors. Vida ventures advisors is the largest institutional shareholder, holding 10.47% of KYTX shares.
KYTX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Kyverna Therapeutics | 26.07% | 7.07% | 66.85% |
| Sector | Healthcare Stocks | 35.49% | 11.75% | 52.76% |
| Industry | Biotech Stocks | 34.83% | 11.71% | 53.46% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vida ventures advisors | 4.52M | 10.47% | $27.14M |
| Gilead sciences | 4.13M | 8.75% | $35.61M |
| Bain capital life sciences investors | 3.11M | 6.60% | $26.84M |
| Aigh capital management | 2.00M | 4.24% | $17.26M |
| Deerfield management company, l.p. (series c) | 2.00M | 4.24% | $17.26M |
| Vanguard group | 1.78M | 4.10% | $16.74M |
| Price t rowe associates inc /md/ | 1.56M | 3.30% | $13.42M |
| Balyasny asset management | 1.13M | 2.39% | $9.71M |
| Millennium management | 1.01M | 2.13% | $8.68M |
| Insight group | 989.05K | 2.10% | $8.54M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Vida ventures advisors | 4.52M | 92.41% | $27.14M |
| Caxton | 18.77K | 4.03% | $162.01K |
| Propel bio management | 644.42K | 3.52% | $5.59M |
| Bain capital life sciences investors | 3.11M | 2.42% | $26.84M |
| Aigh capital management | 2.00M | 2.35% | $17.26M |
| Gilead sciences | 4.13M | 1.68% | $35.61M |
| Catalio capital management, lp | 586.91K | 0.65% | $3.52M |
| Mbb public markets i | 614.48K | 0.63% | $5.30M |
| Insight group | 989.05K | 0.60% | $8.54M |
| Nano cap new millennium growth fund l p | 52.00K | 0.42% | $448.76K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Aigh capital management | 2.00M | 2.35% | 500.00K |
| Marshall wace, llp | 605.51K | 0.01% | 469.91K |
| Vanguard group | 1.78M | 0.00% | 458.63K |
| Millennium management | 1.01M | 0.00% | 412.14K |
| Susquehanna group, llp | 577.60K | 0.00% | 338.77K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Novo | - | - | -1.85M |
| Adage capital partners gp | 500.00K | 0.01% | -1.17M |
| Franklin resources | - | - | -677.59K |
| Alyeska investment group | - | - | -600.00K |
| Rfg advisory | - | - | -445.20K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vanguard fiduciary trust | 224.58K | 0.00% | 224.58K | $1.94M |
| Invesco | 186.67K | 0.00% | 186.67K | $1.61M |
| Y-intercept (hong kong) | 114.84K | 0.02% | 114.84K | $991.08K |
| Wesbanco bank | 110.30K | 0.03% | 110.30K | $951.89K |
| Man group | 53.54K | 0.00% | 53.54K | $462.08K |
Sold Out
| Holder | Change |
|---|---|
| Ifp advisors | -16.00 |
| Sbi securities | -22.00 |
| Parallel advisors | -26.00 |
| Rothschild investment | -50.00 |
| Sterling capital management | -186.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 53 | -50.00% | 12,294,874 | -64.00% | 26 | 0.42% | 30 | -53.85% | 12 | -45.45% |
| Dec 31, 2025 | 62 | -21.52% | 14,501,210 | -36.11% | 33 | 1.21% | 39 | 21.88% | 12 | -53.85% |
| Sep 30, 2025 | 76 | 1.33% | 22,548,873 | 0.47% | 52 | 1.94% | 30 | -26.83% | 26 | 8.33% |
| Jun 30, 2025 | 79 | -10.23% | 23,198,522 | -10.03% | 53 | 1.51% | 44 | 4.76% | 24 | -4.00% |
| Mar 31, 2025 | 88 | -1.12% | 25,809,724 | -9.40% | 59 | 1.37% | 41 | -26.79% | 25 | 92.31% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Dec 18, 2025 | SEIDENBERG BETH C | - | Buy | $1000.00K |
| Dec 18, 2025 | Westlake BioPartners Opportunity Fund I, L.P. | - | Buy | $1000.00K |
| Dec 15, 2025 | Walker Karen Marie | Chief Technology Officer | Sell | $292.78K |
| Feb 12, 2024 | GILEAD SCIENCES, INC. | - | Buy | $20.02M |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | - |
| 2026 Q1 | - | - |
| 2025 Q4 | 2 | 1 |
| 2025 Q2 | - | - |
| 2025 Q1 | - | - |
KYTX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools